HC Wainwright Has Pessimistic Outlook of CDTX Q1 Earnings

Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) - Analysts at HC Wainwright cut their Q1 2025 EPS estimates for Cidara Therapeutics in a research report issued on Monday, March 10th. HC Wainwright analyst E. Arce now anticipates that the biotechnology company will post earnings of ($5.45) per share for the quarter, down from their prior estimate of ($5.13). HC Wainwright has a "Buy" rating and a $35.00 price objective on the stock. The consensus estimate for Cidara Therapeutics' current full-year earnings is ($8.74) per share. HC Wainwright also issued estimates for Cidara Therapeutics' Q2 2025 earnings at ($1.08) EPS, Q3 2025 earnings at ($0.69) EPS, Q4 2025 earnings at ($1.34) EPS, FY2025 earnings at ($7.12) EPS, FY2026 earnings at ($14.64) EPS, FY2027 earnings at ($16.66) EPS and FY2028 earnings at ($4.73) EPS.

Cidara Therapeutics (NASDAQ:CDTX - Get Free Report) last announced its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($5.38) earnings per share for the quarter, missing analysts' consensus estimates of ($5.28) by ($0.10). Cidara Therapeutics had a negative net margin of 289.05% and a negative return on equity of 69.64%.

A number of other research analysts have also weighed in on CDTX. Royal Bank of Canada began coverage on shares of Cidara Therapeutics in a research note on Friday, December 13th. They issued an "outperform" rating and a $34.00 price target on the stock. WBB Securities lifted their price objective on shares of Cidara Therapeutics from $40.00 to $45.00 and gave the company a "strong-buy" rating in a report on Thursday, December 5th. Needham & Company LLC reiterated a "buy" rating and issued a $35.00 price objective on shares of Cidara Therapeutics in a report on Friday, March 7th. Finally, Cantor Fitzgerald upgraded shares of Cidara Therapeutics to a "strong-buy" rating in a report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, four have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $36.40.

Remove Ads

Cidara Therapeutics Stock Performance

Shares of CDTX opened at $21.00 on Wednesday. Cidara Therapeutics has a twelve month low of $10.00 and a twelve month high of $28.42. The firm's 50 day moving average price is $22.35 and its two-hundred day moving average price is $17.64. The firm has a market cap of $147.99 million, a P/E ratio of -0.82 and a beta of 0.88.

Hedge Funds Weigh In On Cidara Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Point72 Asia Singapore Pte. Ltd. bought a new position in Cidara Therapeutics during the fourth quarter worth $56,000. Northern Trust Corp boosted its position in Cidara Therapeutics by 6.8% during the fourth quarter. Northern Trust Corp now owns 33,957 shares of the biotechnology company's stock worth $913,000 after purchasing an additional 2,170 shares during the period. Point72 Asset Management L.P. bought a new position in Cidara Therapeutics during the fourth quarter worth $165,000. Geode Capital Management LLC boosted its position in Cidara Therapeutics by 22.7% during the third quarter. Geode Capital Management LLC now owns 52,898 shares of the biotechnology company's stock worth $569,000 after purchasing an additional 9,771 shares during the period. Finally, OMERS ADMINISTRATION Corp bought a new position in Cidara Therapeutics during the fourth quarter worth $339,000. 35.82% of the stock is owned by institutional investors.

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.